Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and ...

One Conway woman is continuing to fight for her life after being diagnosed with Pulmonary Fibrosis in her battle with long ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendations by the trial’s independent Data Safety ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown cause in a study.

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Chair and CEO of Insmed Inc. (NASDAQ:INSM), recently executed a significant stock transaction amid the company's impressive 178% stock surge over the past year. According to a recent SEC filing, Lewis ...

The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...

Action Global Communications has been named Agency of the Year and Social Media Agency of the Year at the Cyprus Digital ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...